Amgen Inc. is analyzed in a bullish thesis by Magnus Ofstad, highlighting its diverse drug portfolio and growth potential, particularly with the promising MariTide obesity treatment. Despite debt concerns, Amgen's strong pipeline and potential for growth make it an attractive investment choice.